01
Human-centered system design
We prioritize human iPSC-derived and primary-cell-informed biology to improve relevance over simplified, single-compartment approaches.
Human-relevant translational biology
Building the next generation of cardio-renal disease models.
Corelia Bio is developing HETS™ — a human engineered tissue system designed to capture bidirectional heart–kidney signaling, disease-relevant stress biology, and translational response patterns that conventional preclinical models often miss.
Dual-organ
Heart–kidney interaction in one human-relevant platform
Multi-omics
Transcriptomic, proteomic, metabolomic, and secretome layers
Translational
Built for target validation, biomarker discovery, and screening
HETS™ platform concept
A modular, human-cell-based cardio-renal system designed for mechanistic clarity and decision-ready readouts.
Cardiac compartment
Engineered myocardial tissue
Human iPSC-derived cardiomyocytes with stromal and vascular components, enabling force, electrophysiology, and fibrosis-relevant phenotyping.
↔
Cross-talk
Cross-talk
Renal compartment
Kidney tissue module
Human renal cell systems built to study stress responses, transport biology, inflammation, and disease-associated remodeling.
Integrated readouts
Function · morphology · secreted factors · omics signatures · drug response profiles
Designed for early translational de-risking, hypothesis generation, and partner-ready study packages.
Why Corelia Bio
Translational models should reflect the biology that drives patient risk.
Cardio-renal disease is shaped by multi-organ signaling, fibrosis, inflammation, metabolic stress, and endothelial dysfunction. Corelia Bio is focused on building experimental systems that make these interactions more measurable, more human-relevant, and more decision-useful.
02
Mechanism + function
HETS™ links phenotypic outputs with molecular signatures, enabling a stronger bridge between target biology and translational strategy.
03
Partnership-oriented execution
Our platform is structured to support target validation, biomarker exploration, compound profiling, and co-development studies.
Applications
A platform built for discovery teams working in complex cardio-metabolic disease.
Corelia Bio is positioning HETS™ as both a strategic R&D platform and a foundation for future therapeutic programs.
A
Target validation
Interrogate pathway relevance in a controlled, multi-tissue context before expensive downstream development decisions.
- Fibrosis and remodeling biology
- Metabolic and inflammatory stress responses
- Cross-organ signaling hypotheses
B
Biomarker discovery
Capture secreted factors, transcriptional states, and response signatures that can inform translational biomarker strategies.
- Secretome-linked discovery
- Response stratification concepts
- Mechanistically anchored datasets
C
Compound profiling
Evaluate efficacy, rescue patterns, and potential liabilities using readouts aligned with disease-relevant functional endpoints.
- Phenotypic rescue experiments
- Comparative candidate ranking
- Decision-ready translational packages
Pipeline vision
Platform-first today, therapeutic optionality tomorrow.
Corelia Bio’s near-term focus is platform validation and strategic collaboration, while preserving the opportunity to advance internal cardio-renal programs over time.
CR-101
Small-molecule fibrosis modulation
Early concept directed toward cardio-renal fibrosis biology and translational de-risking in human tissue systems.
CR-201
RNA-based metabolic–inflammation program
Concept-stage program centered on disease signaling networks relevant to diabetic and chronic kidney complications.
CR-301
Intercellular communication biology
Exploratory biologic concept focused on endothelial–fibroblast communication and human disease mechanism mapping.
Founder
Ronald St-Louis, PhD
Senior scientist and project leader with extensive experience across cardiometabolic disease, translational research, target validation, and human-relevant discovery strategies in academia and industry.
Corelia Bio reflects a conviction that next-generation preclinical systems must become more human, more integrative, and more useful for high-stakes therapeutic decisions.
→
What Corelia Bio is building
A differentiated cardio-renal innovation layer at the intersection of tissue engineering, translational biology, and decision-enabling data.
∞
How we want to work
With pharma, biotech, translational centers, and innovation hubs that value mechanism, clinical relevance, and platform leverage.
Δ
Current stage
Early-stage company formation, platform articulation, partnership outreach, and pre-seed / translational ecosystem engagement.
✓
Near-term objective
Establish strategic collaborations and proof-of-value studies that validate HETS™ as a platform for complex disease R&D.
Contact
Let’s explore a scientific or strategic collaboration.
Use the form to start a conversation about partnerships, pilot studies, platform validation, or early-stage funding discussions.
Company
Corelia Bio
Focus
Human cardio-renal disease modeling · translational discovery · biomarker strategy
Base
Germany